Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.
Intellia Therapeutics hosted a webcast for investors and analysts titled 'Readying Lonvo-z for Patients with HAE' to discuss the development and commercialization strategy for its CRISPR-based therapy, lonvoguran ziclumeran. The presentation focused on the clinical data and market potential for lonvo-z in treating hereditary angioedema (HAE).
Intellia Therapeutics reported a net loss of $127.5 million for the third quarter of 2026, driven by a decrease in collaboration revenue and increased general and administrative expenses. The company strengthened its balance sheet during the nine months ended September 30, 2026, through a follow-on public offering and new debt issuance, resulting in total cash, cash equivalents, and marketable securities of approximately $614.8 million.
Intellia Therapeutics reported Q3 2026 financial results, highlighting the FDA's acceptance and Priority Review of the BLA for lonvo-z with a PDUFA date of March 10, 2027. The company completed enrollment in its MAGNITUDE-2 Phase 3 trial for ATTRv-PN and expects its current cash position to fund operations into 2028.
Counterparty
Regeneron Pharmaceuticals, Inc.
Term
Q3 2026
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead. We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”
John Leonard, M.D., Intellia President and Chief Executive Officer
Intellia Therapeutics President and CEO John M. Leonard Sells $108K of Stock
John M. Leonard, President and CEO, sold 9,000 shares of Intellia Therapeutics, Inc. at $11.99 a share, worth $108K in total on Nov 2, 2026. Shares held after the trade: 1,138,064 (-0.8%).
Intellia Therapeutics VP, CAO Michael P. Dube Sells $23.2K of Stock
Michael P. Dube, VP, CAO, sold 1,864 shares of Intellia Therapeutics, Inc. at $12.43 a share, worth $23.2K in total on Oct 2, 2026. Shares held after the trade: 65,022 (-2.8%).